Portage Biotech Inc Total Assets
Portage Biotech Inc total assets. Based on the latest financial reports, Portage Biotech Inc (PRTG) holds total assets worth $2.71 Million USD as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see PRTG stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Portage Biotech Inc (1998–2025)
Total assets of Portage Biotech Inc from 1998 to 2025. This chart illustrates how Portage Biotech Inc's total assets have evolved over time, based on quarterly financial data. See PRTG stock price and chart for real-time trading data and today's change.
Portage Biotech Inc - Asset Composition Analysis
Portage Biotech Inc Total Assets Breakdown (March 2025)
Portage Biotech Inc total assets breakdown as of March 2025. Portage Biotech Inc's total assets of $2.71 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 75.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1998–2025)
This chart illustrates how Portage Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Portage Biotech Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Portage Biotech Inc's current assets represent 100.0% of total assets in 2025, an increase from 9.3% in 1998.
- Cash Position: Cash and equivalents constituted 75.1% of total assets in 2025, up from 9.3% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Portage Biotech Inc Competitors by Total Assets
Key competitors of Portage Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Portage Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.08 | 2.00 | 2.26 |
| Quick Ratio | 3.08 | 2.00 | 2.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.81 Million | $3.13 Million | $1.98 Million |
Portage Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Portage Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.34 |
| Latest Market Cap to Assets Ratio | 4.81 |
| Asset Growth Rate (YoY) | -71.4% |
| Total Assets | $2.23 Million |
| Market Capitalization | $10.71 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Portage Biotech Inc's assets at a significant premium (4.81x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Portage Biotech Inc's assets decreased by 71.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Portage Biotech Inc (1998–2025)
The table below shows the annual total assets of Portage Biotech Inc from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $2.23 Million | -71.40% |
| 2024-03-31 | $7.78 Million | -92.15% |
| 2023-03-31 | $99.13 Million | -49.08% |
| 2022-03-31 | $194.66 Million | +11.32% |
| 2021-03-31 | $174.86 Million | +0.97% |
| 2020-03-31 | $173.17 Million | -0.31% |
| 2019-03-31 | $173.72 Million | +1636.63% |
| 2018-03-31 | $10.00 Million | -83.30% |
| 2017-03-31 | $59.90 Million | +374.34% |
| 2016-03-31 | $12.63 Million | +166.66% |
| 2015-03-31 | $4.74 Million | -10.02% |
| 2014-03-31 | $5.26 Million | +53.41% |
| 2013-03-31 | $3.43 Million | -54.34% |
| 2012-03-31 | $7.51 Million | -21.91% |
| 2011-03-31 | $9.62 Million | -5.86% |
| 2010-03-31 | $10.22 Million | +710.24% |
| 2009-03-31 | $1.26 Million | -75.22% |
| 2008-03-31 | $5.09 Million | -12.01% |
| 2007-03-31 | $5.78 Million | +23.72% |
| 2006-03-31 | $4.68 Million | +11.45% |
| 2005-03-31 | $4.20 Million | +78.28% |
| 2004-03-31 | $2.35 Million | +11945.54% |
| 2003-03-31 | $19.54K | -84.92% |
| 2002-03-31 | $129.54K | -77.53% |
| 2001-03-31 | $576.55K | -67.07% |
| 2000-03-31 | $1.75 Million | +917.21% |
| 1999-03-31 | $172.11K | +296.99% |
| 1998-03-31 | $43.35K | -- |
About Portage Biotech Inc
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor … Read more